LPS-BioSciences provides detoxified LPS such as MPLA or Monophosphoryl Lipid A derivated from various LPS species.
A modified form of lipid A, the biologically active part of Gram-negative bacterial lipopolysaccharide (LPS) endotoxin, and a Toll-like receptor 4 (TLR4) agonist, with potential immunostimulatory activity. As a vaccine adjuvant, monophosphoryl lipid A (MPLA) stimulates both cellular and humoral responses to the vaccine antigen. Compared to LPS, MPLA exerts a similar immunostimulatory activity but with reduced toxicity.
MPL(c) is used by GSK in AS0X adjuvant system to boost vaccine efficacy through stimulation of innate immunity.
By stimulating the immune system, lipopolysaccharides can be used as immune adjuvants. The lipidic part, initially anchors in the bacterial membrane, gives a complex with MD2 protein and allows the attachment of the LPS to the TLR4 receptor on the surface of antigen presenting cells. This fixing stimulates the innate immune system by cytokines secretion, which is necessary to generate an adaptive immune response (Caroff et al. 2002).
This adjuvant capacity of TLR4 ligands is involved in the development of new vaccines. The adjuvant capacity of detoxified Lipid A molecules is well known and got FDA approval in 2009 to boost vaccine efficiency from several GSK vaccines. For many years, Monophosphoril Lipid A has shown its efficiency and its safety for being used an adjuvant in many vaccines. It has now become a reference for new adjuvants.
LPS-BioSciences can produce MPLA molecules derivated from various Lipid A species.
We are glad to offer our expertise to all interested partners in the development of MPLA molecules or other projects concerning Endotoxins.
Feel free to contact us for further information.